Usefulness of perflubutane microbubble-enhanced ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical trial

Uemura, Hiroji; Sano, Futoshi; Nomiya, Akira; Yamamoto, Toshihiro; Nakamura, Masafumi; Miyoshi, Yasuhide; Miki, Kenta; Noguchi, Kazumi; Egawa, Shin; Homma, Yukio; Kubota, Yoshinobu

doi:10.1007/s00345-012-0833-1

Cited by 36 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it not clear whether the TIC values are useful for the precise assessment of cancer aggressiveness, which is commonly estimated by the Gleason score and largely influences PCa management2122. Moreover, the contrast-enhanced CETRUS findings for the PCa lesions showed various patterns according to tumour vascularity2324 and aggressiveness2526; this is indicative of the heterogeneity of this cancer. In our study, incorporating TICs enabled the differentiation of low-grade tumours (n = 23) from high-grade ones (n = 31) (Fig.…”

Section: Discussionmentioning

confidence: 99%

Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves

Huang

Zhu

Zhou

et al. 2016

Sci Rep

View full text Add to dashboard Cite

To assess the role of time-intensity curves (TICs) of the normal peripheral zone (PZ) in the identification of biopsy-proven prostate nodules using contrast-enhanced transrectal ultrasound (CETRUS). This study included 132 patients with 134 prostate PZ nodules. Arrival time (AT), peak intensity (PI), mean transit time (MTT), area under the curve (AUC), time from peak to one half (TPH), wash in slope (WIS) and time to peak (TTP) were analyzed using multivariate linear logistic regression and receiver operating characteristic (ROC) curves to assess whether combining nodule TICs with normal PZ TICs improved the prediction of prostate cancer (PCa) aggressiveness. The PI, AUC (p < 0.001 for both), MTT and TPH (p = 0.011 and 0.040 respectively) values of the malignant nodules were significantly higher than those of the benign nodules. Incorporating the PI and AUC values (both, p < 0.001) of the normal PZ TIC, but not the MTT and TPH values (p = 0.076 and 0.159 respectively), significantly improved the AUC for prediction of malignancy (PI: 0.784–0.923; AUC: 0.758–0.891) and assessment of cancer aggressiveness (p < 0.001). Thus, all these findings indicate that incorporating normal PZ TICs with nodule TICs in CETRUS readings can improve the diagnostic accuracy for PCa and cancer aggressiveness assessment.

show abstract

Section: Discussionmentioning

confidence: 99%

Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves

Huang

Zhu

Zhou

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Microbubbles for diagnosis and treatment of breast, prostate, and liver cancer, among others, have been tested in clinical trials with promising results 24 . Sonazoid ® microbubbles were shown to improve the accuracy of diagnosis of prostate cancer, which could reduce the number of biopsies patients need to receive to achieve a similar diagnostic result 31 . In Japan, Sonazoid ® was also used in a phase III clinical trial to compare its diagnostic potential of focal breast lesions against unenhanced ultrasound and contrast enhanced MRI (Figure 2) 32 .…”

Section: Clinical Applications Of Ultrasound Contrast Agentsmentioning

confidence: 99%

Ultrasound imaging beyond the vasculature with new generation contrast agents

Perera

Hernandez

Zhou

et al. 2015

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Current commercially available ultrasound contrast agents are gas-filled, lipid- or protein-stabilized microbubbles larger than 1 μm in diameter. Because the signal generated by these agents is highly dependent on their size, small yet highly echogenic particles have been historically difficult to produce. This has limited the molecular imaging applications of ultrasound to the blood pool. In the area of cancer imaging, microbubble applications have been constrained to imaging molecular signatures of tumor vasculature and drug delivery enabled by ultrasound-modulated bubble destruction. Recently, with the rise of sophisticated advancements in nanomedicine, ultrasound contrast agents, which are an order of magnitude smaller (100-500 nm) than their currently utilized counterparts, have been undergoing rapid development. These agents are poised to greatly expand the capabilities of ultrasound in the field of targeted cancer detection and therapy by taking advantage of the enhanced permeability and retention phenomenon of many tumors and can extravasate beyond the leaky tumor vasculature. Agent extravasation facilitates highly sensitive detection of cell surface or microenvironment biomarkers, which could advance early cancer detection. Likewise, when combined with appropriate therapeutic agents and ultrasound-mediated deployment on demand, directly at the tumor site, these nanoparticles have been shown to contribute to improved therapeutic outcomes. Ultrasound's safety profile, broad accessibility and relatively low cost make it an ideal modality for the changing face of healthcare today. Aided by the multifaceted nano-sized contrast agents and targeted theranostic moieties described herein, ultrasound can considerably broaden its reach in future applications focused on the diagnosis and staging of cancer.

show abstract

“…TBx had a positive overall detection rate of 30.9%, whereas the overall detection was only 6.9% with the 12-core TRUS-guided biopsies [2]. Nontargeted ultrasound microbubbles were studied by Uemura et al [3] who performed targeted prostate biopsies with microbubbles in 71 patients. Although there was a significant difference in cancer detection rate by TBx between two cohorts with PSA less than 10 ng/ml (22.9%) and PSA of at least 10 ng/ml (52.2%), the added value of CE-TRUS was relatively small [3].…”

Section: Transrectal Ultrasoundmentioning

confidence: 98%

“…Nontargeted ultrasound microbubbles were studied by Uemura et al [3] who performed targeted prostate biopsies with microbubbles in 71 patients. Although there was a significant difference in cancer detection rate by TBx between two cohorts with PSA less than 10 ng/ml (22.9%) and PSA of at least 10 ng/ml (52.2%), the added value of CE-TRUS was relatively small [3]. Thus, the literature in CE-TRUS appears promising but somewhat contradictory.…”

Section: Transrectal Ultrasoundmentioning

confidence: 99%

Advances in imaging modalities in prostate cancer

Bouchelouche

Türkbey²,

Choyke³

2015

Current Opinion in Oncology

View full text Add to dashboard Cite

Several advances in the imaging of PCa have been made during the past year. In particular, important clinical developments have been reported in multiparametric MRI, PET/computed tomography, and PET/MRI. The continuing development of imaging techniques in PCa has the potential to optimize treatment of PCa. However, the optimal imaging strategies for each of the major clinical scenarios in PCa have not yet been identified.

show abstract

Usefulness of perflubutane microbubble-enhanced ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical trial

Cited by 36 publications

References 23 publications

Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves

Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves

Ultrasound imaging beyond the vasculature with new generation contrast agents

Advances in imaging modalities in prostate cancer

Contact Info

Product

Resources

About